KD Logo

A company insider recently sold 25,000 shares of Krystal Biotech Inc [KRYS]. Should You also Consider to Sale?

Krystal Biotech Inc’s filing revealed that its President, R&D Krishnan Suma unloaded Company’s shares for reported $4.39 million on Jun 11 ’24. In the deal valued at $175.77 per share,25,000 shares were sold. As a result of this transaction, Krishnan Suma now holds 1,587,262 shares worth roughly $293.64 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Krishnan Suma sold 25,000 shares, generating $4,393,901 in total proceeds. Upon selling the shares at $175.76, the President, R&D now owns 1,525,882 shares.

Before that, Krishnan Krish S sold 25,000 shares. Krystal Biotech Inc shares valued at $4,394,161 were divested by the President and CEO at a price of $175.77 per share. As a result of the transaction, Krishnan Krish S now holds 1,587,262 shares, worth roughly $293.64 million.

Citigroup downgraded its Krystal Biotech Inc [KRYS] rating to a Neutral from a a Buy in a research note published on August 06, 2024; the price target was increased to $204 from $195. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in mid November with a ‘”a Buy”‘ rating. Cantor Fitzgerald began covering KRYS with “an Overweight” recommendation on October 24, 2023. Citigroup started covering the stock on October 12, 2023. It rated KRYS as “a Buy”.

Price Performance Review of KRYS

On Tuesday, Krystal Biotech Inc [NASDAQ:KRYS] saw its stock fall -1.43% to $185.00. Over the last five days, the stock has lost -0.95%. Krystal Biotech Inc shares have risen nearly 49.12% since the year began. Nevertheless, the stocks have risen 49.15% over the past one year. While a 52-week high of $219.34 was reached on 07/26/24, a 52-week low of $93.95 was recorded on 02/22/24. SMA at 50 days reached $194.65, while 200 days put it at $158.40.

Levels Of Support And Resistance For KRYS Stock

The 24-hour chart illustrates a support level at 182.56, which if violated will result in even more drops to 180.12. On the upside, there is a resistance level at 188.64. A further resistance level may holdings at 192.28. The Relative Strength Index (RSI) on the 14-day chart is 42.16, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -7.90, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.79%. Stochastics %K at 16.66% indicates the stock is a buying.

How much short interest is there in Krystal Biotech Inc?

A steep rise in short interest was recorded in Krystal Biotech Inc stocks on 2024-08-15, dropping by -0.12 million shares to a total of 3.54 million shares. Yahoo Finance data shows the prior-month short interest on 2024-07-15 was 3.67 million shares. There was a decline of -3.43%, which implies that there is a negative sentiment for the stock.

The most recent change occurred on September 07, 2023 when Berenberg began covering the stock and recommended ‘”a Buy”‘ rating along with a $154 price target.

Most Popular